Amplia gets nod for new cancer drug trial ahead of US push
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
We haven't written up this one. The Sydney Morning Herald has the full story — the link below goes straight to it.